Travere Therapeutics (TVTX) Acquisitions (2014 - 2016)

Travere Therapeutics' (TVTX) quarterly Acquisitions came in at $115000.0 in Q4 2016, down 77.0% on a QoQ basis from $500000.0 in Q2 2016.

Travere Therapeutics (TVTX) Acquisitions (2014 - 2016) Analysis & Trends

Travere Therapeutics (TVTX) has 3 years of Acquisitions data on file, last reported at $115000.0 in Q4 2016.

Quarterly Acquisitions changed N/A year-over-year to $115000.0 in Q4 2016, while the trailing twelve-month figure through Dec 2017 was $115000.0 (down 81.3% YoY) and the FY2020 annual result came in at $95.3 million, changed N/A from the prior year.
Acquisitions slipped to $115000.0 in Q4 2016, from $500000.0 in the prior quarter.
In the past five years, Acquisitions ranged from a high of $33.4 million in Q1 2015 to a low of $115000.0 in Q4 2016.
A 3-year average of $15.8 million and a median of $14.8 million in 2014 frame the typical range for Acquisitions.
The widest YoY moves for Acquisitions: up 14.68% in 2015, down 14.68% in 2015.
Tracing TVTX's Acquisitions over 3 years: stood at $29.2 million in 2014, then gained by 14.68% to $33.4 million in 2015, then sank by 99.66% to $115000.0 in 2016.
The last three Acquisitions figures came in at $115000.0 (Q4 2016), $500000.0 (Q2 2016), and $33.4 million (Q1 2015), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Travere Therapeutics	5.85 Bn	5.85 Bn	162.52 Mn	-

Download Data